BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

• Main Authors: A. Barnadas (Author), M. Muñoz (Author), M. Margelí (Author), J. I. Chacón (Author), J. Cassinello (Author), S. Antolin (Author), E. Adrover (Author), M. Ramos (Author), E. Carrasco (Author), M. A. Jimeno (Author), B. Ojeda (Author), X. González (Author), S. González (Author), M. Constenla (Author), J. Florián (Author), A. Miguel (Author), A. Llombart (Author), A. Lluch (Author), M. Ruiz-Borrego (Author), R. Colomer (Author), S. Del Barco (Author), On behalf of GEICAM, Spanish Breast Cancer Group (Author)
• Format: Book
• Published: SpringerOpen, 2019-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Abstract Background Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM. Methods Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL. Results Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0-1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity. Conclusions BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patients. Trial registration NCT03847220. Retrospectively registered on clinicaltrials.gov (February the 20th 2019).

Item Description

10.1186/s41687-019-0161-y
2509-8020